首页> 外文期刊>Toxicology Letters: An International Journal Providing a Forum for Original and Pertinent Contributions in Toxicology Research >Single- and repeated-dose toxicity studies on the novel HIV maturation inhibitor QF-036 in Sprague-Dawley rats
【24h】

Single- and repeated-dose toxicity studies on the novel HIV maturation inhibitor QF-036 in Sprague-Dawley rats

机译:关于Sprague-Dawley大鼠的新型HIV成熟抑制剂QF-036的单一和重复剂量毒性研究

获取原文
获取原文并翻译 | 示例
           

摘要

QF-036 is a novel human immunodeficiency virus (HIV) maturation inhibitor that is a lupine triterpenoid derivative. The objective of this study was to evaluate the safety of QF-036. A single oral toxicity and a 4-week repeated oral toxicity were investigated in Sprague-Dawley (SD) rats. The single oral toxicity study of QF-036 in SD rats showed that no mortality or visible pathological changes were noted at doses of 100, 300, and 1000 mg/ kg. QF-036 exhibited a non-lineartoxicokinetic profile over the dose range of 100-1000 mg/kg in the single dose study, and a saturation trend appeared at doses of 100 and 300 mg/kg. In the 4-week oral toxicity and toxicokinetic study, SD rats were given 0, 50, 100, and 200 mg/kg QF-036 once daily for 4 weeks, followed by a 4week recovery period. No mortality or significant effects on food consumption, body weight, or behavior were observed. In addition, there were no test article-related changes in hematology, clinical biochemistry and histopathology. The no observed adverse effect level (NOAEL) was 200 mg/kg. The toxicokinetic study demonstrated a dose-dependent increase in the systemic exposure to QF-036 after 4 weeks of oral administration. There were no marked sex differences or drug accumulation observed for repeated doses of QF-036.
机译:QF-036是一种新型人类免疫缺陷病毒(HIV)成熟抑制剂,其是羽扇豆三萜类衍生物。本研究的目的是评估QF-036的安全性。在Sprague-Dawley(SD)大鼠中研究了单一的口腔毒性和4周重复的口服毒性。 SD大鼠QF-036的单个口服毒性研究表明,在100,300和1000mg / kg的剂量下没有发现死亡率或可见的病理学变化。 QF-036在单剂量研究中,在100-1000mg / kg的剂量范围内显示出非线性毒性曲线,并且饱和趋势以100和300mg / kg的剂量出现。在4周的口服毒性和诱导毒性研究中,SD大鼠每天一次给予0,50,100和200mg / kg QF-036,持续4周,其次是4周的恢复期。没有观察到对食品消费,体重或行为的死亡率或显着影响。此外,血液学,临床生物化学和组织病理学没有测试文章相关变化。未观察到的不良影响水平(Noael)为200mg / kg。诱导研究在口服给药4周后系统暴露于QF-036的剂量依赖性增加。对于重复剂量的QF-036,没有明显的性别差异或药物积累。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号